GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on ...

A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, manufactured by Novo Nordisk. Reuters Eli Lilly said Wednesday that its obesity drug Zepbound ...

An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...

But a recent head-to-head trial comparing Zepbound vs. Wegovy provided new insights into their effectiveness, making the choice slightly clearer. The findings? Zepbound led to an average weight ...

The medications are so common now, two-thirds of the clinic’s calls for insurance pre-authorizations are for the big three: ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...

The FDA suggests that prescribed users also reduce their calorie intake and increase their exercise The weight loss drug ...

The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to ... Along with Novo Nordisk's GLP-1 drugs Ozempic and Wegovy, this class of ...

Lilly’s obesity drug, Zepbound, showed an average weight loss of 20.2%, which was superior to 13.7% for Novo Nordisk’s Wegovy (semaglutide) in a first-ever head-to-head obesity study ...

Zepbound raked in more than $3bn in sales in the first three quarters this year, compared to DKK 43.7bn ($6.17bn) that Novo generated from its obesity portfolio, consisting of Wegovy and Saxenda ...

Eli Lilly said its obesity drug Zepbound led to more weight loss than its main rival, Novo Nordisk's Wegovy, in the first head-to-head clinical trial on the two weekly injections. The findings ...